Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush

Kura Oncology (NASDAQ:KURA) had its target price decreased by analysts at Wedbush from $38.00 to $36.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 323.03% from the company’s previous close.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. Leerink Partners set a $20.00 price target on shares of Kura Oncology and gave the company an “outperform” rating in a research report on Tuesday, January 13th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Finally, Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.71.

Kura Oncology Stock Down 0.5%

KURA opened at $8.51 on Friday. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $12.49. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average price is $8.79 and its 200-day moving average price is $9.38. The company has a market cap of $740.54 million, a P/E ratio of -3.43 and a beta of 0.22.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.50). The company had revenue of $17.34 million for the quarter, compared to the consensus estimate of $34.71 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. On average, equities analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 8,180 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider directly owned 267,274 shares in the company, valued at $2,261,138.04. This trade represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 7,142 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $60,421.32. Following the sale, the senior vice president directly owned 145,167 shares in the company, valued at approximately $1,228,112.82. The trade was a 4.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 59,794 shares of company stock worth $537,176. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Assenagon Asset Management S.A. grew its position in shares of Kura Oncology by 37.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,265,030 shares of the company’s stock worth $11,196,000 after buying an additional 345,951 shares during the period. Sector Gamma AS bought a new stake in Kura Oncology during the third quarter worth about $3,880,000. Nan Fung Trinity HK Ltd. bought a new stake in Kura Oncology during the third quarter worth about $2,043,000. Los Angeles Capital Management LLC purchased a new stake in Kura Oncology in the second quarter worth about $450,000. Finally, CWM LLC increased its stake in shares of Kura Oncology by 185.9% during the third quarter. CWM LLC now owns 118,363 shares of the company’s stock valued at $1,048,000 after purchasing an additional 76,957 shares in the last quarter.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI commercial launch shows early demand and fast payer access — Kura reported $2.1M of net product revenue from ~5 weeks of sales and ~80% private payer coverage within 90 days, supporting near-term adoption expectations. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Regulatory/IP and partner milestones reduce execution risk — KOMZIFTI added to the FDA Orange Book (patents through 2044) and product shipments triggered a $135M Kyowa Kirin milestone plus additional $30M milestones for Phase 3 dosing, bolstering near-term cash. Kura Oncology anticipates $7B AML opportunity
• Positive Sentiment: Balance sheet and collaboration support runway — $667.2M cash + expected $180M in collaboration payments should fund programs into pivotal Phase 3 readouts (reduces near-term financing risk). Q4/FY2025 Financial Results
• Neutral Sentiment: Pipeline catalysts expected in 2026 — multiple data readouts and ongoing Phase 3/combination trials (KOMET-017, KOMET-007 expansions, FIT-001) could materially expand addressable markets but are timing-dependent. KURA Q4 2025 Earnings Call Highlights
• Negative Sentiment: Big earnings and revenue miss — Q4 EPS -$0.92 vs. consensus -$0.42 and total revenue $17.34M vs. est. $34.71M; collaboration revenue fell year-over-year, pressuring near-term valuation. MarketBeat Q4 Earnings Summary
• Negative Sentiment: Widening losses and higher costs — Net loss rose to $81M in Q4 as R&D and SG&A increased for commercialization and trial advancement, raising concerns about longer-term profitability before potential revenue ramps. Q4 Financials
• Negative Sentiment: Safety profile and label risks could limit uptake — KOMZIFTI carries a boxed warning for differentiation syndrome and notable QTc prolongation/other serious AEs; these issues can complicate real-world use and restrain market penetration. Safety Information
• Negative Sentiment: Insider selling and mixed institutional flows — Significant insider sales reported and large, offsetting institutional position changes suggest some investor rotation/uncertainty. QuiverQuant Launch/Ownership Summary

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.